[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

January 1, 2017, Vol 3, No. 1, Pages 3-127

In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2017;3(1):3. doi:10.1001/jamaoncol.2016.1662
Viewpoint

Should Chemotherapy Be Used in Nonmetastatic Prostate Cancer?

Abstract Full Text
JAMA Oncol. 2017;3(1):11-12. doi:10.1001/jamaoncol.2016.3623

This Viewpoint argues against the early use of docetaxel chemotherapy in the treatment of prostate cancer.

Avoiding Undertreatment of Aggressive Prostate Cancer by Early Use of Chemotherapy

Abstract Full Text
JAMA Oncol. 2017;3(1):13-14. doi:10.1001/jamaoncol.2016.3634

This Viewpoint argues for early use of chemotherapy in patients diagnosed with prostate cancer.

Drug Price Inflation and the Cost of Assisted Death for Terminally Ill Patients—Death With Indignity

Abstract Full Text
JAMA Oncol. 2017;3(1):15-16. doi:10.1001/jamaoncol.2016.3842

This Viewpoint describes the rising cost of Death With Dignity Act prescriptions which makes assisted death a less-viable option for patients with fewer than 6 months to live.

Taking Care of Our Friends and Neighbors DeVita’s The Death of Cancer and the Challenge of Letting Go

Abstract Full Text
JAMA Oncol. 2017;3(1):16-17. doi:10.1001/jamaoncol.2016.3076

This Viewpoint evaluates The Death of Cancer and the role of oncologists as friends or relatives of patients with cancer.

Editorial

Minimal Residual Disease as a Potential Surrogate End Point—Lingering Questions

Abstract Full Text
JAMA Oncol. 2017;3(1):18-20. doi:10.1001/jamaoncol.2016.3112

Atypical Ductal HyperplasiaWhat Is the Current Risk for Developing Breast Cancer?

Abstract Full Text
JAMA Oncol. 2017;3(1):20-21. doi:10.1001/jamaoncol.2016.3136

Who Benefits From a Tumor Bed Boost After Whole-Breast Radiotherapy?

Abstract Full Text
JAMA Oncol. 2017;3(1):21-22. doi:10.1001/jamaoncol.2016.3137
Original Investigation

Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple MyelomaA Meta-analysis

Abstract Full Text
JAMA Oncol. 2017;3(1):28-35. doi:10.1001/jamaoncol.2016.3160

This meta-analysis examines the prognostic value of minimal residual disease assessment as associated with survival outcomes in patients with newly diagnosed multiple myeloma.

Subsequent Breast Cancer Risk Following Diagnosis of Atypical Ductal Hyperplasia on Needle Biopsy

Abstract Full Text
JAMA Oncol. 2017;3(1):36-41. doi:10.1001/jamaoncol.2016.3022

This cohort study uses data from the Breast Cancer Surveillance Consortium to evaluate the 10-year cumulative risk of breast cancer in women with atypical ductal hyperplasia that was diagnosed on needle biopsy vs excisional biopsy.

Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost TrialA Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2017;3(1):42-48. doi:10.1001/jamaoncol.2016.3031

This reanalysis of the EORTC “boost vs no boost” trial examines the long-term impact of prognostic factors on ipsilateral breast tumor recurrence in patients treated with breast-conserving therapy.

Association Between Androgen Deprivation Therapy and Risk of Dementia

Abstract Full Text
JAMA Oncol. 2017;3(1):49-55. doi:10.1001/jamaoncol.2016.3662

This cohort study uses clinical informatics to examine the association of androgen deprivation therapy for prostate cancer with the development of dementia.

Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1–Deficient Malignant Pleural MesotheliomaA Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2017;3(1):58-66. doi:10.1001/jamaoncol.2016.3049

This phase 2 randomized clinical trial examines the effect of arginine deprivation plus best supportive care vs best supportive care alone in patients with argininosuccinate synthetase 1–deficient malignant pleural mesothelioma.

Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles AdministeredA Post Hoc Analysis of the Mainsail Study

Abstract Full Text
JAMA Oncol. 2017;3(1):68-75. doi:10.1001/jamaoncol.2016.3000

This study uses data from a clinical trial comparing docetaxel vs mitoxantrone for metastatic castration-resistant prostate cancer to investigate the association between the number of docetaxel cycles and overall survival in patients who benefitted from docetaxel.

Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian CancerAnalysis of the National Cancer Database

Abstract Full Text
JAMA Oncol. 2017;3(1):76-82. doi:10.1001/jamaoncol.2016.4411

This study uses the US National Cancer Database to compare overall survival following primary cytoreductive surgery vs neoadjuvant chemotherapy in women with advanced-stage epithelial ovarian cancer.

Association of Improved Locoregional Control With Prolonged Survival in Early-Stage Extranodal Nasal-Type Natural Killer/T-Cell Lymphoma

Abstract Full Text
JAMA Oncol. 2017;3(1):83-91. doi:10.1001/jamaoncol.2016.5094

This cohort study assesses whether improved locoregional control is associated with a survival benefit in patients with early-stage extranodal natural killer/T-cell lymphoma in China.

Effect of a Patient-Centered Communication Intervention on Oncologist-Patient Communication, Quality of Life, and Health Care Utilization in Advanced CancerThe VOICE Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2017;3(1):92-100. doi:10.1001/jamaoncol.2016.4373

This study describes the effectiveness of a combined intervention that included oncologist communication training and coaching for patients with advanced cancer and caregivers in improving patient-centered communication.

Brief Report

Association of Regional Intensity of Ductal Carcinoma In Situ Treatment With Likelihood of Breast Preservation

Abstract Full Text
JAMA Oncol. 2017;3(1):101-104. doi:10.1001/jamaoncol.2016.2164

This population-based study, using the SEER and Medicare databases, looks at the association between regional practices in use of radiotherapy for ductal in situ breast cancer with later use of mastectomy.

Invited Commentary

Observational Cohort Studies and the Challenges of In Silico Experiments

Abstract Full Text
JAMA Oncol. 2017;3(1):55-57. doi:10.1001/jamaoncol.2016.3478

The ADAM TrialVisiting the Road Less Traveled

Abstract Full Text
JAMA Oncol. 2017;3(1):66-67. doi:10.1001/jamaoncol.2016.2854
Review

Harnessing the Immune System as a Therapeutic Tool in Virus-Associated Cancers

Abstract Full Text
has active quiz
JAMA Oncol. 2017;3(1):106-112. doi:10.1001/jamaoncol.2016.4574

This review examines the mechanisms of viral carcinogenesis, with an emphasis on the viral evasion of the host immune system, and discusses how to harness the immune system as a therapeutic tool in select malignant cancers.

From The JAMA Network

Laparoscopic Rectal Resection—Ready for Prime Time?

Abstract Full Text
JAMA Oncol. 2017;3(1):113-114. doi:10.1001/jamaoncol.2016.3202

This commentary compares the results of the ALaCaRT study with 3 large randomized clinical trials comparing laporoscopic vs open surgery for rectal cancer resection.

Outcomes of Open vs Laparoscopic Rectal Cancer Resection

Abstract Full Text
JAMA Oncol. 2017;3(1):115-116. doi:10.1001/jamaoncol.2016.3205

This commentary reviews the results of the ACOSOG Z6051 randomized clinical trial, which compared outcomes of laparoscopic resection vs open resection in patients with rectal cancer.

JAMA Oncology Clinical Challenge

New Yellow Plaques in a Patient Taking Pembrolizumab

Abstract Full Text
JAMA Oncol. 2017;3(1):119-120. doi:10.1001/jamaoncol.2016.4365

A woman in her 70s with stage 3A squamous cell carcinoma of the lung was enrolled in a clinical trial in which she received combination therapy with pembrolizumab and an investigational agent; 3 months into treatment, she developed multiple thick, mildly pruritic, yellow, hyperkeratotic plaques on her lower extremities. What is your diagnosis?

JAMA Oncology Clinical Evidence Synopsis

Lymphadenectomy for Treatment of Early-Stage Endometrial Cancer

Abstract Full Text
JAMA Oncol. 2017;3(1):117-118. doi:10.1001/jamaoncol.2016.4873

This Clinical Evidence Synopsis summarizes a Cochrane review that analyzes the association between lymphadenectomy and survival, disease recurrence, and surgical morbidity in women with presumed early-stage, low-grade endometrial carcinoma.

Research Letter

Capecitabine and the Risk of Fingerprint Loss

Abstract Full Text
JAMA Oncol. 2017;3(1):122-123. doi:10.1001/jamaoncol.2016.2638

This cohort study assesses whether fingerprint loss is an unexpectedly frequent adverse effect of treatment with capecitabine.

Long-term Survival After Chemoradiotherapy Without Surgery for Rectal AdenocarcinomaA Word of Caution

Abstract Full Text
JAMA Oncol. 2017;3(1):123-125. doi:10.1001/jamaoncol.2016.3424

This cohort study examines a hospital-based national cancer registry to assess whether chemoradiotherapy plus proctectomy vs chemoradiotherapy without surgery is associated with worse overall survival in patients with nonmetastatic rectal adenocarcinoma.

Comment & Response

Human Papillomavirus Genotypes Conferring Poor Prognosis in Head and Neck Squamous Cell Carcinoma

Abstract Full Text
JAMA Oncol. 2017;3(1):125. doi:10.1001/jamaoncol.2016.3409

Human Papillomavirus Genotypes Conferring Poor Prognosis in Head and Neck Squamous Cell Carcinoma—Reply

Abstract Full Text
JAMA Oncol. 2017;3(1):125-126. doi:10.1001/jamaoncol.2016.3397

Unanswered Questions Concerning Locoregional Irradiation in Breast Cancer

Abstract Full Text
JAMA Oncol. 2017;3(1):126-127. doi:10.1001/jamaoncol.2016.3412

Unanswered Questions Concerning Locoregional Irradiation in Breast Cancer—Reply

Abstract Full Text
JAMA Oncol. 2017;3(1):127. doi:10.1001/jamaoncol.2016.3322

Unanswered Questions Concerning Locoregional Irradiation in Breast Cancer—Reply

Abstract Full Text
JAMA Oncol. 2017;3(1):127. doi:10.1001/jamaoncol.2016.3383
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2017;3(1):4. doi:10.1001/jamaoncol.2016.1663
×